Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Hardman Johnston International Equity. This analysis is provided for institutional research purposes only and is not investment advice.
"The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and financials positions."
In Q4 2025, the Hardman Johnston International Equity Composite returned 4.34% net of fees, modestly underperforming its MSCI EAFE Net Index benchmark (4.86%), but finishing a stellar full year with a 42.10% net return (outperforming the benchmark's 31.22%). Healthcare (Sandoz, AstraZeneca) and Financials (Standard Chartered) led quarterly sector gains, whereas Industrials and Consumer Discretionary detracted. The firm executed one initiation (Weir Group PLC) and two liquidations (Nexans SA, Deutsche Telekom AG) during the quarter. In its outlook, the firm remains focused on secular growth opportunities in defense, global infrastructure, and AI-led productivity, while maintaining a cautious stance on portfolio concentration and geopolitical volatility.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Growth Outlook
Market outlook remains above average conviction: The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Risk Appetite
Risk appetite posture is moderate conviction: The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Forward Guidance
Forward guidance signal: The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Language Signal
Tone analysis indicates above average conviction language: The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
Time Horizon
Investment time horizon reflects a high conviction orientation. The fund achieved a strong 42.10% net return for full year 2025 despite minor Q4 underperformance, with the portfolio demonstrating strong execution across core healthcare and fina...
